Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Suzuki, Eiji ^a   Kataoka, Tatsuki R ^a   Hirata, Masahiro ^a   Kawaguchi, Kosuke ^a   Nishie, Mariko ^a   Haga, Hironori ^a   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; HER2; Trastuzumab; Trogocytosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PACLITAXEL; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; CD14 ANTIGEN; CD56 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER PATIENT; CELL INTERACTION; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SYSTEMIC THERAPY; TREATMENT RESPONSE; TROGOCYTOSIS; TUMOR MICROENVIRONMENT; UPREGULATION; VOLUNTEER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST NEOPLASMS; CELL MEMBRANE; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD14; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN BIOSYNTHESIS; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84924078492     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1041-3     Document Type: Article

References (27)

1. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol. 2008;181(11):8120-32.
2. Griffin Jr FM, Griffin JA, Silverstein SC. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med. 1976;144(3):788-809.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72.
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.
6. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2011;22(6):1302-7.
7. Panchision DM, Chen HL, Pistollato F, Papini D, Ni HT, Hawley TS. Optimized flow cytometric analysis of central nervous system tissue reveals novel functional relationships among cells expressing CD133, CD15, and CD24. Stem Cells. 2007;25(6):1560-70.
8. Brown R, Kabani K, Favaloro J, Yang S, Ho PJ, Gibson J, et al. CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood. 2012;120(10):2055-63.
9. Huang JF, Yang Y, Sepulveda H, Shi W, Hwang I, Peterson PA, et al. TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. Science. 1999;286(5441):952-4.
10. Hudrisier D, Bongrand P. Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J. 2002;16(6):477-86.
11. Wetzel SA, Parker DC. MHC transfer from APC to T cells following antigen recognition. Crit Rev Immunol. 2006;26(1):1-21.
12. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol. 2007;7(3):238-43.
13. Riond J, Elhmouzi J, Hudrisier D, Gairin JE. Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8(+) T cells. Scand J Immunol. 2007;66(4):441-50.
14. Ahmed KA, Munegowda MA, Xie Y, Xiang J. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol Immunol. 2008;5(4):261-9.
15. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007;109(5):2040-8.
16. Sabzevari H, Kantor J, Jaigirdar A, Tagaya Y, Naramura M, Hodge J, et al. Acquisition of CD80 (B7-1) by T cells. J Immunol. 2001;166(4):2505-13.
17. Vahlenkamp TW, Bull ME, Dow JL, Collisson EW, Winslow BJ, Phadke AP, et al. B7+CTLA4+ T cells engage in T-T cell interactions that mediate apoptosis: a model for lentivirus-induced T cell depletion. Vet Immunol Immunopathol. 2004;98(3-4):203-14.
18. Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res. 2008;68(6):2006-13.
19. Abouzahr S, Bismuth G, Gaudin C, Caroll O, Van Endert P, Jalil A, et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci U S A. 2006;103(5):1428-33.
20. Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002;8(2):347-53.
21. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006;12(2):424-31.
22. Carlin LM, Eleme K, McCann FE, Davis DM. Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses. J Exp Med. 2001;194(10):1507-17.
23. Vanherberghen B, Andersson K, Carlin LM, Nolte-'t Hoen EN, Williams GS, Hoglund P, et al. Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci U S A. 2004;101(48):16873-8.
24. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014;26(2):259-71.
25. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705-13.
26. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775.
27. Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, et al. Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer. J Clin Oncol. 2014;32(33):3753-61.